Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
Mainz, Germany
University hospital in Mainz, Rhineland-Palatinate
Langenbeckstraße 1, 55131 Mainz
About Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Incyte Corporation
10
Hoffmann-La Roche
5
Pfizer
2
University of Heidelberg Medical Center
2
Incyte Biosciences International Sàrl
1
Clinical Trials at Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
During the past decade, Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 11 clinical trials were completed, i.e. on
average, 68.8% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 7 clinical trials were completed. i.e. 175%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
2008-01-01
2013-03-01
Completed
53
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
2011-03-01
2018-06-01
Completed
101
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
2011-07-06
2021-07-30
Completed
1,401
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
2014-12-01
2018-03-16
Completed
163
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
2015-06-01
2021-06-24
Completed
564
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
2015-12-30
2020-04-24
Terminated
447
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
2018-03-14
2023-06-30
Active, not recruiting
126
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
2017-12-18
2023-03-31
Active, not recruiting
110
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" #1 sponsor was "Incyte Corporation" with 10 trials, followed by "Hoffmann-La Roche" with 5 trials
sponsored, "Pfizer" with 2 trials sponsored, "University of Heidelberg Medical Center" with 2 trials sponsored and "Incyte Biosciences International Sàrl"
with 2 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii"
#1 collaborator was "AbbVie" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
According to Clinical.Site data, the most researched conditions in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" are
"Multiple Myeloma" (4 trials), "Lymphoma" (3 trials), "Follicular Lymphoma" (2 trials), "Non-Hodgkin's Lymphoma" (2 trials) and "Cancer of Unknown Primary Site" (1 trials). Many other conditions were trialed in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" in a lesser frequency.
Clinical Trials Intervention Types at Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
Most popular intervention types in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" are "Drug" (20 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Bortezomib" (3 trials), "Dexamethasone" (3 trials), "Parsaclisib" (3 trials), "Placebo" (3 trials) and "Atezolizumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
The vast majority of trials in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" are
20 trials for "All" genders.
Clinical Trials Status at Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
Currently, there are NaN active trials in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii".
undefined are not yet recruiting,
3 are recruiting,
7 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 8 completed trials in Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, 3 "Phase 1"
clinical trials were conducted, 11 "Phase 2" clinical
trials and 9 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".